Open Access Repository

Variation in the pharmacokinetics of glucosamine in healthy individuals

Asthana, C ORCID: 0000-0001-6273-2723, Peterson, GM ORCID: 0000-0002-6764-3882, Shastri, MD ORCID: 0000-0002-1012-2779 and Patel, RP ORCID: 0000-0001-9344-1013 2020 , 'Variation in the pharmacokinetics of glucosamine in healthy individuals' , Rheumatology , pp. 1-5 , doi: 10.1093/rheumatology/keaa418.

Full text not available from this repository.

Abstract

Objectives:Clinical trial data for the efficacy of glucosamine in OA are conflicting. Reportedly, Rotta-manufactured glucosamine products are more likely to be effective, and a possible explanation is greater bioavailability than other brands. Specifically, the aim was to compare the steady-state pharmacokinetics of Rotta- and non-Rotta-manufactured glucosamine products in healthy volunteers and examine the interindividual variability.Methods:In a crossover design, healthy adult participants ingested 1500 mg/day of a Rotta (DONA powder sachets; imported by Mylan Health, Carole Park, QLD, Australia) and a non-Rotta (glucosamine sulphate 1500 mg one-a-day tablet; Blackmores, Warriewood, NSW, Australia) glucosamine product/brand individually for 6 days. Blood samples were collected immediately before and for 12 h after the ingestion of the last dose of each brand and analysed to determine plasma levels of glucosamine. The pharmacokinetic parameters at steady state [including the minimum (Css min) and maximum (Css max) plasma concentration of glucosamine, time to reach Css max post-dosing (Tss max) and area under the plasma concentration vs time curve (AUCss 0–12)] for each brand were calculated and statistically compared.Results:Fourteen participants [mean age 35.5 years (S.D.M 8.8)] were recruited (64.2% males). No significant differences were observed in the pharmacokinetic parameters between the two brands. However, for both brands, the coefficient of variation for Css min, Tss max and AUCss 0–12 exceeded 20%, indicating considerable differences in the parameters between participants. No significant association of the pharmacokinetic parameters was observed with various dosing- and participant-related variables.Conclusion:Substantial interindividual differences in the absorption and elimination of glucosamine could be a cause of variable clinical outcomes in OA.

Item Type: Article
Authors/Creators:Asthana, C and Peterson, GM and Shastri, MD and Patel, RP
Keywords: pharmacokinetic, plasma, HPLC, osteoarthritis, glucosamine, pharmacokinetics, absorption, elimination, variability
Journal or Publication Title: Rheumatology
Publisher: Oxford Univ Press
ISSN: 1462-0324
DOI / ID Number: 10.1093/rheumatology/keaa418
Copyright Information:

Copyright 2020 the authors

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP